Nasal Spray News and Research

RSS

Study reveals the LDLR pathway as a ubiquitous metabolic vulnerability in high grade gliomas

New research has shown that the blood vessels that feed aggressive brain tumors have receptors that could allow a new type of drug-containing nanoparticle to be used to starve the tumors of the energy they use to grow and spread, and also cause other disruptions to their adapted existence, even killing themselves.

7 Mar 2023

A call to action proposed for health providers to ensure widest distribution, easy availability of naloxone

In 2021, 100,306 Americans died from drug overdoses – a 28.5 percent increase from the prior year – with 75,673 attributed to opioids.

16 Feb 2023

Simple nasal spray effective at easing sleep-disordered breathing in children

A simple nasal spray significantly reduced snoring and breathing difficulties in children and halved the number needing to have their tonsils removed, according to a new study.

17 Jan 2023

Scientists pinpoint the routes taken by SARS-CoV-2 to enter and exit cells in our nasal cavity

Somebody just coughed on you. On a plane. At a dinner party. In a supermarket line. If only there were a "morning after" nasal spray that could knock out respiratory viruses' ability to colonize your nose and throat.

5 Jan 2023

NY docs are now required to prescribe naloxone to some patients on opioid painkillers

Without opioid painkillers to dull the ache in his knees and other joints, Arnold Wilson wouldn't be able to walk half a block. The 63-year-old former New York City nurse has crippling arthritis for which he takes OxyContin twice a day and oxycodone when he needs additional relief.

5 Jan 2023

People eligible for free winter vaccines urged to come forward over the Christmas holiday

All those eligible for their free winter vaccines are being urged to come forward as soon as possible for their free jabs over the Christmas holiday, as hospitalizations for flu and Covid continue to rise.

23 Dec 2022

Exploring environmental viral emissions after SARS-CoV-2 Human challenge

A recent study captured the dynamics of pre-symptomatic SARS-CoV-2 emissions and reported the extent, magnitude, and routes of viral transmission are heterogeneous, with nasal mucosa being an important source of viral transmission.

21 Dec 2022

Nasal antibodies decline nine months after COVID-19 infection, study finds

A new study finds that antibodies produced in the nose decline nine months after COVID-19 infection, while antibodies found in the blood last at least a year.

20 Dec 2022

NIH establishes research network to test harm reduction strategies in community settings

To address the overdose crisis in the United States, the National Institutes of Health has established a research network that will test harm reduction strategies in different community settings to inform efforts to help save lives.

16 Dec 2022

New chemical compound shows promise to reverse effects of potentially deadly drugs

Drug overdoses in the United States have risen sharply in the last two decades. Nearly 92,000 people died from overdoses of illegal drugs and prescription opioids in 2020-;more than five times the number of deaths in the year 2000-;and synthetic opioids like fentanyl are one of the main culprits.

16 Dec 2022

Study reveals biological mechanism to explain why respiratory viruses spike in colder seasons

Researchers at Mass Eye and Ear and Northeastern University have discovered a previously unidentified immune response inside the nose that fights off viruses responsible for upper respiratory infections.

7 Dec 2022

Self-service vending machine filled with harm reduction supplies helps prevent overdoses

More than 107,000 Americans died from drug overdose in 2021, highlighting the need for evidence-based interventions.

6 Dec 2022

Engineered proteins can be delivered as a nasal spray to protect against and treat COVID-19

COVID-19 has had a lasting global health impact that continues to challenge the health care system. As the coronavirus continues to mutate, the current COVID-19 prevention strategies are plagued with supply chain disruptions, high vaccine manufacturing costs and inconvenient vaccine administration methods.

29 Nov 2022

All eligible people urged to get vaccinated due to higher rates of flu cases than usual

All those eligible for the flu vaccine have been urged to come forward as cases rise to levels not seen since before the pandemic.

24 Nov 2022

Cat allergen immunotherapy works better and more quickly when combined with monoclonal antibody

An experimental approach to enhancing a standard cat allergy treatment made it more effective and faster acting, and the benefits persisted for a year after treatment ended, a study supported by the National Institutes of Health has found.

11 Oct 2022

Oxford researchers report findings from Phase 1 clinical trial of intranasal COVID-19 vaccine

Researchers from the University of Oxford have today reported new findings from a Phase 1 clinical trial studying the safety and immune response of an intranasally-administered vaccine against COVID-19.

11 Oct 2022

Brain stimulation combined with nasal spray containing nanoparticles can improve stroke recovery

In a recent study, researchers from Xi'an Jiaotong-Liverpool University and other universities in China have reported that brain stimulation combined with a nose spray containing nanoparticles can improve recovery after ischemic stroke in an animal model.

29 Sep 2022

New compound triggers the same anti-depressant action as rapidly acting psychedelic drugs

While illegal for recreational use, psychedelic drugs are showing great promise as treatments for severe depression and anxiety, as well as alcohol addiction and other conditions.

28 Sep 2022

High levels of mucosal antibodies in the airways reduce the risk of omicron infection

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three doses of the SARS-CoV-2 vaccine.

14 Sep 2022

Parenteral-prime mucosal boost an effective strategy to protect against SARS-CoV-2

In a recent study published in the journal eBioMedicine, researchers in Denmark and Sweden administered a cationic liposome-adjuvanted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein subunit vaccine as a subcutaneous (s.c.) prime-intranasal (i.n.) boost strategy to elicit mucosal immune responses among SARS-CoV-2-infected Syrian hamsters.